Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 20/20 | 0.79 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.79 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.79 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.79 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.79 |
| ▸ | LPAR3 | Q9UBY5 | 13/20 | 0.66 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343602 | 0.92 | LPAR1 (0.77) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL12123688 | 0.92 | LPAR1 (0.77) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| Bms-986020 SCHEMBL344742 | 0.89 | LPAR1 (1.00) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| Bms-986020 SCHEMBL14590 | 0.89 | LPAR1 (1.00) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| Bms-986020 SCHEMBL343068 | 0.89 | LPAR1 (1.00) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL342813 | 0.89 | LPAR1 (0.69) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL14794837 | 0.88 | LPAR1 (0.98) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL22257227 | 0.88 | LPAR1 (0.98) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL12123670 | 0.87 | LPAR1 (0.86) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL15280709 | 0.87 | LPAR1 (0.86) | LPAR1ABCC3ABCC4ABCB11CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-8058300-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | claimed |
| US-20130253019-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS OR DISEASES OF THE EYE | AMIRA PHARMACEUTICALS, INC. | 2013-09-26 | — | — | US | disclosed |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011159632-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS OR DISEASES OF THE EYE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159635-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST FOR THE TREATMENT OF DERMAL CONDITIONS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159633-A1 | INHALABLE FORMULATIONS OF LYSOPHOSPHATDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-8058300-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058300-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885ABCC3 2717/4885ABCC4 2854/4885 |
| US-20130253019-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS OR DISEASES OF THE EYE | LPAR1, LPAR2, LPAR5 | LPAR1 1/4885ABCC3 3873/4885ABCC4 4136/4885 |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885ABCC3 2717/4885ABCC4 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.